Biotechnology companies apply biological science to develop products, services and technologies that address challenges in healthcare, agriculture, industry and environmental sustainability.
This category includes companies working on:
Browse 360 UK biotechnology companies below.
Bayesian oncology models for treatment-response prediction and research
Concr is a London biotechnology software company using astrophysics-derived Bayesian AI to model individual cancer biology and predict treatment responses. Its FarrSight platform combines genomic, molecular and clinical datasets in digital twins, supporting research into patient stratification and oncology drug…
Bioabsorbable polymer biomaterials for implantable medical devices
4D Medicine is a UK-based biotechnology company developing bioabsorbable polymer biomaterials for use in implantable medical devices and controlled drug delivery systems. The company’s proprietary polymer platform is designed to enable the creation of degradable medical device components with tunable mechanical…
Organelle engineering platform developing novel crop traits for agriculture
Cytotrait is a biotechnology company developing novel traits for food and agricultural crops. Its MOSS platform introduces genes and gene edits into plant organelles, including chloroplasts and mitochondria, enabling rapid homoplasmy across the plant. The approach aims to improve yield, resilience, disease resistance…
TCR-based bispecific therapeutics for cancer and autoimmune disease
T-Therapeutics is a biotechnology company developing T cell receptor-based therapeutics for cancer and autoimmune disease. Using a humanised TCR mouse platform to generate high-affinity, antigen-specific human T cell receptors, the company engineers bispecific molecules that redirect a patient's own T cells to…
AI-powered drug discovery and repurposing for rare diseases
Healx is a clinical-stage biotech applying AI to drug discovery and repurposing for rare diseases. Its platform analyses drug and disease data at scale to identify novel treatment relationships, enabling multiple discovery programmes to run in parallel. The lead programme targeting neurofibromatosis type 1 entered…
Preclinical therapeutic company targeting tissue fibrosis in allergic asthma
Fibraxis is a preclinical-stage biotechnology company developing a therapeutic for allergic asthma that targets tissue fibrosis in the lung. Spun out of Aston University and supported by SPARK The Midlands, the company builds on research into pericytes, the mesenchymal cells implicated in airway scarring and…
Preimplantation and prenatal genetic testing for reproductive medicine
Juno Genetics is a specialist reproductive genetics laboratory providing preimplantation genetic testing (PGT) services to IVF clinics in the UK and internationally. Using its proprietary next-generation sequencing platform, the company screens embryos for chromosomal abnormalities and single-gene disorders, and…
AI-powered retinal biomarker platform for early detection of eye and brain disease
Novai is a biotechnology company commercialising DARC (Detection of Apoptosing Retinal Cells), a retinal biomarker platform combining a fluorescent biologic with an AI image analysis algorithm to detect single-cell apoptosis in the retina in vivo. FDA and MHRA approved as an exploratory biomarker, DARC enables early…
Programmable iPSC cell therapies for cancer and autoimmunity
Xap Therapeutics is a Cambridge-based biotechnology company developing a synthetic biology platform for next-generation cell therapeutics. The company applies CRISPR technology to engineer induced pluripotent stem cells (iPSCs) into a universal "chassis" cell that can be functionalised with engineered receptors and…
AI-driven AAV capsid engineering for next-generation gene therapy
Lir Therapeutics is an early-stage biotechnology company redesigning adeno-associated virus capsids for gene therapy using an AI-first platform. Its platform integrates high-throughput experimental data generation with machine learning models trained on structural, functional and immunogenicity representations of…
Menstrual blood biomarker test for gynaecological condition diagnosis
Woost is a biotechnology company developing a home test kit and AI-assisted digital platform that uses menstrual blood as a diagnostic matrix for gynaecological conditions. The platform enables women to track condition-relevant biomarkers from self-collected samples, with initial focus on polycystic ovary syndrome.…
Targeted nanoparticle formulations for nucleic acid delivery
XapHe is a biotechnology company developing peptide-based nanoparticles for therapeutic nucleic acid delivery. Its HAWC platform packages RNA and DNA payloads into formulations designed for cell entry and tissue targeting. The company supplies transfection kits and offers custom nanoparticle formulation services for…
Standardised mesenchymal stromal cell therapies for chronic tissue repair
TrophiCell develops cell therapies based on mesenchymal stromal cells, which release signals involved in tissue repair and immune regulation. Its patented production method aims to generate standardised cells at scale from a single donor, addressing variability associated with earlier cell therapy approaches. The…
Glycan-based biological age and inflammaging diagnostics
GlycanAge is a biotechnology company that develops and sells diagnostic tests based on IgG glycan biomarkers. Its flagship product analyses glycans from a finger-prick blood sample to determine a customer's biological age, reflecting the degree of chronic inflammation driving immune ageing. Tests are available…
Oral delivery platform for biologics targeting inflammatory diseases
Intract Pharma is a biotechnology company developing proprietary formulation platforms for the oral delivery of complex biologics including monoclonal antibodies and proteins. The technology enables precision delivery to the colon for local and systemic immunomodulation, targeting gastrointestinal and systemic…
AI-driven isoform sequencing platform for movement disorder and ageing research
Entelo Bio is an Oxford-based biotechnology company developing a proprietary single-cell isoform sequencing and AI platform to decode disease biology in conditions affecting human movement and ageing. Built on research from the University of Oxford's Botnar Institute for Musculoskeletal Sciences, the platform combines…
Non-surgical drug therapy for spinal cord injury recovery
NeuroSolv Therapeutics is a preclinical-stage biotechnology company developing a non-surgical two-part therapy for spinal cord injury. The proposed mechanism combines enzymatic removal of perineuronal nets on spinal cord neurons with treatment of signal-blocking glial scar tissue, enabling new synaptic connections to…
Topical formulations treating atopic dermatitis and inflammatory skin disease
Quodria is a dermatology-focused biotech developing novel topical formulations for skin diseases using nanotechnology-enabled drug delivery. Its lead programme, Q001, is a small molecule galectin-3 inhibitor licensed from University of Liverpool spin-out Galytx, in development as a first-in-class topical treatment for…
Shark-derived single-domain antibody biologics for cancer and inflammation
Elasmogen is a biotechnology company developing next-generation therapeutic biologics based on its proprietary soloMER platform, single-domain antibody-like proteins derived from the shark immune system. soloMERs offer advantages over conventional antibodies in size, stability, and tissue penetration. The pipeline…
Global population genomics platform for drug target discovery and clinical trials
Omnigen Biodata is a biotechnology company operating the Discover Me platform, a global population health and genomics research programme integrating health and genetic data from participants across multiple countries. The platform generates large-scale biodata resources used by pharmaceutical partners to identify…